237 related articles for article (PubMed ID: 35344001)
1. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
[TBL] [Abstract][Full Text] [Related]
2. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q; Xu J; Mu X; Shi Y; Fan H; Li S
Front Endocrinol (Lausanne); 2023; 14():1214334. PubMed ID: 37908750
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Banerjee M; Pal R; Mukhopadhyay S; Nair K
J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
[TBL] [Abstract][Full Text] [Related]
4. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y
Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
Jiao X; Peng P; Zhang Q; Shen Y
Clin Drug Investig; 2023 Dec; 43(12):915-926. PubMed ID: 37938535
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis.
Banerjee M; Pal R; Maisnam I; Mukhopadhyay S
Diabetes Metab Syndr; 2024 Jan; 18(1):102943. PubMed ID: 38211482
[TBL] [Abstract][Full Text] [Related]
7. Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.
Yang W; Wu H; Cai X; Lin C; Luo Y; Hu S; Li Z; Jiao R; Bai S; Liu G; Yang X; Ji L
Obes Rev; 2024 Jun; 25(6):e13725. PubMed ID: 38346789
[TBL] [Abstract][Full Text] [Related]
8. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
Akbari A; Hadizadeh S; Heidary L
J Diabetes Res; 2024; 2024():3212795. PubMed ID: 38529046
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.
Kapoor I; Sarvepalli SM; D'Alessio D; Grewal DS; Hadziahmetovic M
Surv Ophthalmol; 2023; 68(6):1071-1083. PubMed ID: 37454782
[TBL] [Abstract][Full Text] [Related]
10. Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis.
Tan L; Wang Z; Okoth K; Toulis KA; Denniston AK; Singh BM; Crowe FL; Sainsbury C; Wang J; Nirantharakumar K
Front Endocrinol (Lausanne); 2023; 14():1303238. PubMed ID: 38239984
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.
Singh S; Garg A; Tantry US; Bliden K; Gurbel PA; Gulati M
Curr Probl Cardiol; 2024 Mar; 49(3):102403. PubMed ID: 38237815
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Zhao H; Liu Y; Liu M; Xu Y; Ling Q; Lin W; Zhang J; Yan Z; Ma J; Li W; Zhao Y; Yu P; Liu X; Wang J
Drugs; 2023 Sep; 83(14):1293-1307. PubMed ID: 37639180
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
[TBL] [Abstract][Full Text] [Related]
14. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S
Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
Karakasis P; Patoulias D; Pamporis K; Stachteas P; Bougioukas KI; Klisic A; Fragakis N; Rizzo M
Metabolism; 2023 Dec; 149():155710. PubMed ID: 37852529
[TBL] [Abstract][Full Text] [Related]
16. Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.
Sato T; Azuma Y; Ozone C; Okazaki M; Takeda A; Okada M; Futamura K; Hiramitsu T; Goto N; Narumi S; Watarai Y
J Clin Endocrinol Metab; 2023 Sep; 108(10):2597-2603. PubMed ID: 36974363
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.
Yuan X; Gao Z; Hao Z; Ma H; Duan K; Yang C
Medicine (Baltimore); 2023 Oct; 102(43):e35739. PubMed ID: 37904378
[TBL] [Abstract][Full Text] [Related]
18. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
Cai W; Zhang R; Yao Y; Wu Q; Zhang J
Front Public Health; 2024; 12():1277113. PubMed ID: 38356942
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.
Gomes DA; Presume J; de Araújo Gonçalves P; Almeida MS; Mendes M; Ferreira J
Cardiovasc Drugs Ther; 2024 Jan; ():. PubMed ID: 38214869
[TBL] [Abstract][Full Text] [Related]
20. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Liao C; Liang X; Zhang X; Li Y
PLoS One; 2023; 18(8):e0289616. PubMed ID: 37616255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
